a Department of Urology , Radboud University Medical Center , Nijmegen , The Netherlands.
Int J Hyperthermia. 2018 Nov;34(7):988-993. doi: 10.1080/02656736.2017.1406618. Epub 2017 Dec 1.
Non-muscle invasive bladder cancer (NMIBC) is a highly recurrent disease with potential progression to muscle invasive disease despite the standard bladder instillations with mitomycin C (MMC) or Bacille Calmette-Guérin immunotherapy. Therefore, alternatives such as radiofrequency-induced chemohyperthermia (RF-CHT) with MMC are being investigated. The mechanism explaining the efficacy of RF-CHT is only partly understood. We examined whether RF-CHT results in higher MMC tissue concentrations as compared to cold MMC instillation.
Prior to a planned transurethral resection of bladder tumour (TURBT), patients with stage Ta NMIBC were allocated to either (1) cold MMC instillation or (2) RF-CHT. After MMC instillation, three biopsies were taken of both normal and tumour tissue. Biopsies were snap-frozen and MMC tissue concentrations were analysed using ultra-performance liquid chromatography.
Eleven patients were included of which six received RF-CHT. Ten patients had TaG2-LG/HG papillary tumours at pathology. One patient in the RF-CHT group appeared to be free of malignancy and was excluded from the analysis as no tumour biopsies were available. The median MMC concentration in tumour tissue was higher in the RF-CHT group (median 665.00 ng/g vs. 63.75 ng/g, U = 51.0, p = 0.018). Moreover, in both techniques the MMC concentration was lower in normal tissue compared to tumour tissue. Tissue MMC concentration measurements varied substantially within, and between, different patients from the same group.
Intravesical RF-CHT results in higher tumour MMC concentrations vs. cold MMC instillation which contributes to its superior efficacy.
非肌肉浸润性膀胱癌(NMIBC)是一种高度复发性疾病,尽管采用丝裂霉素 C(MMC)或卡介苗免疫疗法进行标准膀胱灌注,但仍有潜在进展为肌肉浸润性疾病的可能。因此,正在研究替代方法,如射频诱导的化学热疗(RF-CHT)联合 MMC。解释 RF-CHT 疗效的机制尚不完全清楚。我们研究了与冷 MMC 灌注相比,RF-CHT 是否会导致更高的 MMC 组织浓度。
在计划进行经尿道膀胱肿瘤切除术(TURBT)之前,将 TaNMIBC 期患者分配至以下两种治疗方案:(1)冷 MMC 灌注或(2)RF-CHT。MMC 灌注后,对正常和肿瘤组织各取 3 个活检。活检组织立即冷冻,采用超高效液相色谱法分析 MMC 组织浓度。
共纳入 11 例患者,其中 6 例接受 RF-CHT。病理检查结果显示 10 例患者为 TaG2-LG/HG 乳头状肿瘤,1 例 RF-CHT 组患者似乎无恶性肿瘤,由于无肿瘤活检,因此被排除在分析之外。RF-CHT 组肿瘤组织中的 MMC 浓度中位数较高(中位数 665.00ng/g 比 63.75ng/g,U=51.0,p=0.018)。此外,在两种技术中,正常组织中的 MMC 浓度均低于肿瘤组织。来自同一组的不同患者之间的 MMC 组织浓度测量值差异很大。
与冷 MMC 灌注相比,膀胱内 RF-CHT 可导致更高的肿瘤 MMC 浓度,从而提高其疗效。